Are We Ready for Psychedelics?

A variety of psychedelic agents have been studied for the clinical purpose of treating psychiatric disorders, such as psilocybin for mood and anxiety disorders and 3,4-methylenedioxy-methamphetamine (MDMA) for PTSD. While they were effective in reducing symptoms, with many participants rating their experiences as among the most profound and meaningful of their lives, neuroimaging studies with these and other psychedelic agents are still in their early stages. Given the strength of these findings, more extensive studies are called for, as are studies in more diverse populations, with additional thought given as to how to deal with the unique legal, ethical, and regulatory issues surrounding the clinical use of these agents.

In this CMEOCast podcast, expert faculty discuss the complex history and focus on the preliminary clinical data that support the use of psychedelics for the management of treatment resistant conditions.

At the end of this CE activity, participants should be able to:
-Evaluate the role of psychedelic agents for the management of mood and anxiety disorders